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NOTE
CHANGE IN REGULATION IS NECESSARY
FOR GENETICALLY ENGINEERED
MOSQUITOES
Insung Hwang*
ABSTRACT
Millions of genetically engineered (GE) mosquitoes could soon be released in
Key West, Florida as an effort to eradicate wild mosquitoes that are transmitters
of diseases such as malaria, dengue, and chikungunya.  Both international and
domestic regulations fail to provide effective regulatory schemes that can facilitate
the application of this technology while ensuring all safety and environmental
aspects are properly addressed.  The Food and Drug Administration’s assertion of
jurisdiction is based on its assessment that the GE mosquitoes are “animal drugs”
under the Federal Food, Drug, and Cosmetic Act.  This is especially troublesome
because the end goal of using these mosquitoes is to prevent diseases in humans,
which are not “animals” under the statute.  Also, the current scheme only regu-
lates the engineered gene inside the mosquito, but not the mosquito itself, and fails
to account for the fact that the mosquito is a living animal that acts separately
and independently from the engineered gene inside.  Moreover, the U.S. Depart-
ment of Agriculture’s voluntary abrogation of jurisdiction is questionable because
it had asserted jurisdiction on other GE insects and accumulated extensive expe-
rience in dealing with such issues.  Instead, Mexico’s approach of establishing a
separate federal-level regulatory body specifically for genetically modified orga-
nisms could be instructive.  No matter what the solution, some change in regula-
tion addressing GE mosquitoes has become even more urgent with the recent
spread of Zika virus in the U.S.
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I. MILLIONS OF GENETICALLY ENGINEERED (GE) MOSQUITOES TO
BE RELEASED IN FLORIDA
Oxitec, a British biotech firm launched by Oxford University research-
ers, is preparing to release millions of genetically engineered (GE) mos-
quitoes in Key West, Florida.1  Oxitec has developed and patented genetic
engineering technology to breed Aedes aegypti, yellow fever mosquitoes,
“with fragments of proteins from the herpes simplex virus and E. coli bacte-
ria as well as genes from coral and cabbage.”2  This technology produces
mosquitoes containing a “self-limiting” gene.3  Unlike female mosquitoes,
male mosquitoes with the self-limiting gene only feed on nectar and do not
bite.4  When released into the wild, those males could breed with female
mosquitoes to produce offspring that would inherit the self-limiting gene
that is activated and kills mosquito larvae before they can fly or bite, thus
decreasing the total population of biting mosquitoes in the environment.5
The rationale for engaging in this extraordinary scientific endeavor is
simple and reasonable: reducing disease transmission.6  “Of all disease-
1. Jennifer Kay, Millions of GMO Insects Could be Set Loose in Florida Keys, ASSOCIATED
PRESS (Jan. 25, 2015 1:22 AM), http://www.bigstory.ap.org/article/078caa7e75df442295e8c3
db634fe9af/millions-gmo-insects-could-be-set-loose-florida-keys.
2. Id.
3. See Oxitec, How It Works, AGRICULTURE, http://www.oxitec.com/health/how-it-works
(last visited Dec. 21, 2016).
4. See id.
5. Id.
6. Oxitec, Overview, OUR SOLUTION, http://www.oxitec.com/our-solution/ (last visited
Dec. 21, 2016).
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transmitting insects, the mosquito is the greatest menace.”7  Mosquitoes
carry and transmit fatal diseases such as malaria, dengue, and chikungunya.8
These diseases alone cause several million deaths and there are hundreds of
millions of new cases every year.9  Over 2.5 billion people around the world
are at risk of contracting malaria.10  In 2015, there were 212 million new
cases of malaria, resulting in 429,000 deaths.11  Dengue and chikungunya
are infamous for inducing excruciating pain.12  A recent study found that
there were 390 million dengue infections annually, with approximately 96
million manifesting clinically.13  To make matters worse, there are no vac-
cines or cures for dengue or chikungunya.14
Mosquito-borne diseases have disproportionately grave impacts on chil-
dren and the poor.  Over one million children die every year from malaria.15
And despite the lack of a definitive relationship between poverty and den-
gue, mosquito-borne diseases bring grave economic impacts on countries,
communities, and families by affecting the health and working capacity of
hundreds of millions of poor people.16  Children miss school due either
directly to contracting malaria or in order to serve as substitute labor for
parents or siblings who have contracted it.17  Children in infected areas have
an average of two to three bouts of malaria each year,18 making the disease
one of the largest drivers of absenteeism among school children in affected
areas, ultimately resulting in higher failure and drop-out rates.19
7. World Health Org. [WHO], World Health Report: Executive Summary, Insect-borne
Diseases (1996), http://www.who.int/whr/1996/media_centre/executive_summary1/en/index9
.html [hereinafter World Health Report].
8. Id.
9. Id.
10. WHO, Vector-borne Diseases, MEDIA CENTRE (Feb. 2016), http://www.who.int/
mediacentre/factsheets/fs387/en/.
11. WHO, Malaria, MEDIA CENTRE, http://www.who.int/mediacentre/factsheets/fs094/
en/ (last updated Dec. 2016).
12. See WHO, Chikungunya, MEDIA CENTRE, http://www.who.int/mediacentre/fact-
sheets/fs327/en/ (last updated Apr. 2016); WHO, Dengue and Severe Dengue, MEDIA CENTRE,
http://www.who.int/mediacentre/factsheets/fs117/en/ (last updated July 2016).
13. WHO, Dengue and Severe Dengue, supra note 12. R
14. Id.; WHO, Chikungunya, supra note 12. R
15. See Healthy Environments for Children Alliance, Issue Brief Series: Vector-borne Dis-
eases, WHO, http://www.who.int/heca/infomaterials/en/vector-borne.pdf (last visited Dec.
5, 2016).
16. Kate Mulligan et al., Is Dengue a Disease of Poverty? A Systematic Review, 109 PATHO-
GENS AND GLOBAL HEALTH 10, 10–18.
17. See Healthy Environments for Children Alliance, supra note 15. R
18. See id.
19. See Jeffrey Sachs & Pia Malaney, The Economic and Social Burden of Malaria, 415
NATURE 680, 683 (2002).
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Mosquito-borne disease is no longer a problem limited to the tropics.
Global warming and ease of travel are threatening to spread the diseases
farther away from the equator.20  This endangers the southernmost U.S.
communities, such as Key West, Florida.21  The recent outbreak of the Zika
virus in a section of Miami Beach is a good example of how Florida is
susceptible to mosquito-borne diseases that originate abroad.22
Currently, one of the prevalent ways of controlling the mosquito popu-
lation is insecticides, which are often applied door-to-door and from heli-
copters.23  However, mosquitoes have grown immune to four of the six
insecticides used to kill them in the Key West area.24  Therefore, developing
new ways of exterminating the mosquito population is absolutely necessary
for the welfare of people living in Florida in order to minimize the risk of
human exposure to mosquitoes carrying lethal viruses.
Even if we assume that society understands the need to implement
groundbreaking technology to prevent its own exposure to deadly diseases,
novel scientific endeavors that incorporate GE organisms tend to create a
great deal of anxiety.25  Although the overwhelming majority of the popula-
tion of mosquitoes to be released in Florida is male, Oxitec admitted that a
tiny percentage of the release batch would contain biting female mos-
quitoes.26  The company claims that nothing will happen if a person is bit-
ten by one of the stray female mosquitoes.27  The company also says that
the environment will not be impacted at all.28  In an attempt to further
ameliorate the public’s anxiety, Oxitec stated that it will take responsibility
if something goes wrong due to the company’s actions or inactions.29  De-
spite these assurances, various civil protests, including an online petition
that has been signed by more than 150,000 people, have arisen in fear that
Oxitec’s application will be approved.30
20. Daniel Chang, Florida Reports Three More Mosquito-Borne Zika Infections in Miami
Beach, MIAMI HERALD (Oct. 5, 2016 4:01 PM), http://www.miamiherald.com/news/health-
care/article106200452.html.
21. Id.
22. Id.
23. Kay, supra note 1.
24. Id.
25. See Lizette Alvarez, A Mosquito Solution (More Mosquitoes) Raises Heat in Florida
Keys, N.Y. TIMES (Feb. 19, 2015), http://www.nytimes.com/2015/02/20/us/battle-rises-in-
florida-keys-over-fighting-mosquitoes-with-mosquitoes.html?_r=0.
26. Id.
27. Id.
28. Id.
29. See id.
30. Mila de Mier, Online Petition: Say No to Genetically Modified Mosquitoes Release in the
Florida Keys, https://www.change.org/p/say-no-to-genetically-modified-mosquitoes-release-
in-the-florida-keys (last visited Dec. 21, 2016) [hereinafter GE Mosquito Petition].
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Leaving aside the questions of safety and efficacy that lend themselves
to scientific inquiry, the goal of this Note is to explore the regulatory mech-
anisms in place for approving Oxitec’s technology, as well as the reasons
why a change in regulation is necessary in order to better reflect the new
technology.  The Food and Drug Administration (FDA), in its preliminary
Finding of No Significant Impact (FONSI), has already concluded that “the
probability that the release of [GE] male mosquitoes would result in toxic
or allergenic effects in humans or other animals is negligible.”31  This meant
that Oxitec still needed one additional approval from the Florida Keys Mos-
quito Control District (FKMCD) Board of Commissioners, which held two
non-binding referendums regarding the proposed mosquito release for Key
Haven and Monroe County residents on November 8, 2016.32  The results
of the referendums were split: the Key Haven residents voted against the
project while the broader Monroe County residents voted in favor.33  Ulti-
mately, the FKMCD board decided that the trials will not take place in Key
Haven but will take place somewhere else in the Key still to be
determined.34
But the development of a safe technology does not require a healthy
regulatory framework.  The Obama administration stated that the regula-
tory scheme governing GE animals “had become outdated and confusing
and did not foster public confidence.”35  While the government continues to
prepare a new system, the emergence of new technologies such as the GE
mosquitoes has exposed weak points of the current regulatory scheme.  This
Note addresses the gaps in that system, and proposes ways to improve the
regulation of technologies involving genetically engineered organisms, such
as the GE mosquitoes, that are designed to address human health risks.
31. FDA, PRELIMINARY FINDING OF NO SIGNIFICANT IMPACT (FONSI) IN SUPPORT OF AN
INVESTIGATIONAL FIELD TRIAL OF OX513A AEDES AEGYPTI MOSQUITOES (2016).
32. Florida Keys Mosquito Control District, Latest Information on the Proposed Oxitec
GM Mosquito Project, GENETICALLY MODIFIED MOSQUITO, http://keysmosquito.org/latest-gm-in-
formation/ (last visited Dec. 21, 2016).
33. Alexandra Sifferlin, Genetically Modified Mosquitoes Divide Florida Residents, TIME
(Nov. 9, 2016), http://time.com/4564304/genetically-modified-mosquitoes-divide-florida-
residents.
34. Greg Allen, Florida Keys Approves Trial of Genetically Modified Mosquitoes to Fight
Zika, NPR (Nov. 20, 2016), http://www.npr.org/sections/health-shots/2016/11/20/5027172
53/florida-keys-approves-trial-of-genetically-modified-mosquitoes-to-fight-zika.
35. Andrew Pollack, White House Orders Review of Rules for Genetically Modified Crops,
N.Y. TIMES (July 2, 2015), http://www.nytimes.com/2015/07/03/business/white-house-or-
ders-review-of-biotechnology-regulations.html (summarizing John P Holdren et al., Improv-
ing Transparency and Ensuring Continued Safety in Biotechnology, WHITE HOUSE BLOG (July 2,
2015 2:57 PM), https://obamawhitehouse.archives.gov/blog/2015/07/02/improving-trans-
parency-and-ensuring-continued-safety-biotechnology).
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II. GE MOSQUITOES ARE MISCHARACTERIZED IN THE CURRENT
DOMESTIC REGULATIONS
Domestic regulations do not sufficiently address many aspects of the
GE mosquito technology.  This section points out that the assertion of ju-
risdiction by the FDA over the GE technology based on the assessment that
the GE mosquitoes are “animal drugs” under the Federal Food, Drug, and
Cosmetic Act (FDCA) is a mischaracterization.  This is because the end
goal of using the GE mosquitoes is to prevent diseases in humans, not
animals.  That end goal might lead to the conclusion that GE mosquitoes
qualify as drugs for humans.  However, human treatment would put the GE
mosquitoes under a different regulatory framework than animal drugs.36
Also, the current scheme regulates the engineered gene inside the mosquito,
but not the mosquito itself.  This fails to account for the fact that the mos-
quito is a living animal that acts separately and independently from the
engineered gene inside.37  Finally, this section discusses that the GE mos-
quitoes are so different from traditional drugs that they might necessitate
the consideration of extra-label use.38
A. GE Mosquitoes Are Regulated as “Animal Drugs” Under the
Federal Statute But Are Actually Human Drugs
Currently, the FDA asserts jurisdiction over the GE mosquitoes be-
cause a genetic modification through introduction of recombinant DNA
(rDNA) in animals is classified as a “new animal drug” under of the FDCA,
the authorizing statute for the FDA.39  A “new animal drug,” under Section
201(v) of the Act, is “any drug intended for use for animals other than man,”
for which the safety and efficacy has not been sufficiently proven.40  “Drug”
is defined in Section 201(g)(1)(C), which includes “articles (other than
food) intended to affect the structure or any function of the body of man or
other animals.”41  The FDA’s interpretation of its authority over genetically
engineered animals through the statute is addressed in its Guidance for
Industry document released in June 2015.42  The FDA’s justification for
asserting its authority is that genetic engineering techniques are “intended
36. See infra Section II.A.
37. See infra Section II.B.
38. See infra Section II.C.
39. Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301–399f (2012).
40. Id. § 321(v).
41. Id. §321(g)(1)(C).
42. FDA, GUIDANCE FOR INDUSTRY #187: REGULATION OF GENETICALLY ENGINEERED ANIMALS
CONTAINING HERITABLE RECOMBINANT DNA CONSTRUCTS, 5–9 (2015) [hereinafter FDA
GUIDANCE].
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to affect the structure or function of the body of the GE animal.”43  There-
fore, according to the FDA, the genetic engineering method used in the
GM mosquitoes is within its jurisdiction provided by the FDCA.
The self-limiting gene does indeed “affect the structure or any function
of the body” of the mosquito.  The male mosquitoes that are genetically
modified in the lab to be released into the wild cannot reach maturity unless
tetracycline is present.44  Scientists artificially feed GE mosquito larvae
with the tetracycline “antidote” in the lab, allowing those mosquitoes to
survive until they are able to mate with female mosquitoes in the wild.45
However, not enough tetracycline is available in the natural environment, so
the offspring that inherit the self-limiting gene die off naturally.46
However, a regulatory mischaracterization of the GE mosquitoes
reveals itself when one considers the other intended purpose of the self-
limiting gene—limiting human exposure to tropical diseases.  Section
201(g)(1)(B) of the FDCA provides another definition of the term “drug” as
“articles intended for use in the diagnosis, cure, mitigation, treatment, or
prevention of disease in man or other animals.”47  The intention to mini-
mize humans’ exposure to tropical diseases might qualify as a “prevention of
disease” under this definition in the FDCA.  If that interpretation of the
statute holds, then the issue of GE mosquitoes would no longer be confined
to the realm of animal drugs.
Drugs for human use are regulated under a different section of the
FDCA.  Using that paradigm, jurisdiction for drug approval would belong
to the Center for Drug Evaluation and Research (CDER) / Center for Bio-
logics Evaluation and Research (CBER) instead of the Center for Veteri-
nary Medicine (CVM).48  In fact, some organizations and individuals such
as Friends of the Earth (FOE) have asserted that “[t]he release of GE mos-
quitoes as an attempt to curb the spread of disease should be considered a
medical trial and must follow the strict laws and guidelines in place to pro-
tect human subjects in medical trials.”49
43. Id. at 6.
44. Oxitec, The Science, OUR SOLUTION, http://www.oxitec.com/our-solution/technology/
the-science/ (last visited Dec. 21, 2016).
45. Id.
46. Id.
47. 21 U.S.C. § 321(g)(1)(B) (2012).
48. FDA, How Drugs are Developed and Approved, DRUGS, http://www.fda.gov/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved (last visited Jan. 21,
2017); FDA, About CBER, ABOUT FDA, http://www.fda.gov/AboutFDA/CentersOffices/Of-
ficeofMedicalProductsandTobacco/CBER/ucm123340.htm (last visited Jan. 21, 2017).
49. Friends of the Earth, Issue Brief: Genetically Engineered Mosquitoes in the U.S., http://
www.foe.org/system/storage/877/df/1/959/Issue_brief_GE_mosquitoes_in_U.S.pdf (last vis-
ited Dec. 21, 2016).
\\jciprod01\productn\M\MEA\6-1\MEA107.txt unknown Seq: 8 12-MAY-17 12:54
292 Michigan Journal of Environmental & Administrative Law [Vol. 6:1
In an attempt to interpret the scope of the term “drug” under the
FDCA, the Court of Appeals for the D.C. Circuit found that “the crux of
FDA jurisdiction over drugs lay in manufacturers’ representations as revela-
tory of their intent.”50  The Second Circuit has also found that “[t]he ven-
dors’ intent in selling the product to the public is the key element in this
statutory definition.”51  This intent is “determined by [the vendors’] expres-
sions or may be shown by the circumstances surrounding the distribution of
the article.”52  Applying these rules to Oxitec’s project, there is no doubt
that the mosquitoes are within the meaning of “drug” under the FDCA.
Oxitec promotes its technology as providing “a proven means of protecting
people from Aedes aegypti and the diseases it spreads,” which is a clear repre-
sentation of the company’s intent to sell the GE mosquitoes as articles that
benefit the public health.53
It remains unresolved whether an article that serves its purpose without
requiring direct contact with the human body can be considered a drug.
The FDCA’s scope regarding its definition of “drug” has been interpreted
broadly by courts in some instances.  For example, the District of D.C. has
categorized balloons containing laughing gas (nitrous oxide) sold in a park-
ing lot at a rock concert as “drugs” because the defendant intended to sell a
“mind-altering” article that affects the structure or function of the body.54
Meanwhile, other courts have construed the term more narrowly.  For ex-
ample, the Second Circuit, in a per curium opinion, affirmed the position of
the lower court that it would be absurd to interpret the statute literally
when applied to cigarettes, since “any article which, used in the manner
anticipated by the manufacturer thereof, comes into contact with any of the
senses may be said to be an article ‘intended to affect the functions of the
body of man.’”55  That court reviewed the legislative history of FDCA to
reach the conclusion that “Congress, had the matter been considered, would
not have intended cigarettes to be included [as a drug].”56
When defining “drug” in 1938, Congress could not possibly have fore-
seen that the statute would reach genetic engineering technologies that pre-
vent human diseases without requiring any direct contact with humans.
Rather than hypothesizing what Congress would have done in this circum-
stance, it is more relevant to consider GE mosquitoes in light of courts’
50. Action on Smoking & Health v. Harris, 655 F.2d 236, 238–39 (D.C. Cir. 1980).
51. Nat’l Nutritional Foods Ass’n. v. Mathews, 557 F.2d 325, 333 (2d Cir. 1976).
52. 21 C.F.R. § 201.128 (2016).
53. Oxitec, Overview, supra note 6. R
54. United States v. Travia, 180 F. Supp. 2d 115, 118–19 (D.D.C. 2001).
55. FTC v. Liggett & Myers Tobacco Co., 108 F. Supp. 573, 576 (S.D.N.Y. 1952),
aff’d, 203 F.2d 955 (2d Cir. 1953).
56. FTC v. Liggett & Myers Tobacco Co., 108 F. Supp. at 577.
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analysis of whether in vitro diagnostic methods that do not come into direct
contact with the human body are “drugs” under the FDCA.
Two seminal cases reach opposite conclusions on in vitro diagnostic
methods.  The first case, decided by the Supreme Court, involved an antibi-
otic sensitivity disc that comes in contact with cultures of a patient’s virus in
vitro and screens for the optimal antibiotic to administer to patients by
checking the sensitivity of the patient’s virus to a particular antibiotic.57
The Court explained that “the disc is used, in conjunction with a patient’s
specimen, in laboratory work exclusively, and never comes in contact with
any part of the patient’s body itself.”58  Despite that mechanism, the Court
decided that the disc is indeed a “drug” under the FDCA because “the pa-
tient will tend to derive less benefit and perhaps some harm from a particu-
lar antibiotic if, though the drug itself was properly batch-tested, it was not
the proper antibiotic to use” and that “Congress fully intended that the Act’s
coverage be as broad as its literal language indicates.”59
Contrarily, the District of New Jersey in 1975 held that an in vitro preg-
nancy kit is not a drug.60  The pregnancy kit worked by reacting fresh urine
with solutions contained in bottles provided in the kit.61  The court empha-
sized that “[t]his test is in glass, outside the body, using body fluids availa-
ble by ordinary bodily processes (i.e., ‘in vitro’ to use the technical term).
The test does not involve the injection or ingestion of any material in the
human body itself (i.e., ‘in vivo’).”62  The court decided that the pregnancy
test kit is not a “drug” under the FDCA because pregnancy is not a disease,
rather it is a “normal physiological function of all mammals.”63  The preg-
nancy kit, the court stated, is distinguishable from the antibiotic sensitivity
disc case because the latter has “life-and-death risks involved in achieving a
correct diagnosis.”64
Neither case discussed the intended use of “prevention” delineated in
the definition of “drug” under the FDCA; both focus on “diagnosis” and
“treatment.”  However, the District of New Jersey failed to address the pos-
sibility of using pregnancy test kits as a prevention measure.  By allowing
women to find out whether they are pregnant at an early stage of preg-
nancy, they can protect not only their own health, but also that of the fetus.
Perhaps the court did not address this question because there was no cir-
57. See United States v. Article of Drug Bacto-Unidisk, 394 U.S. 784, 784 (1969).
58. Id. at 787.
59. Id. at 798–99.
60. United States v. Article of Drug-Ova II, 414 F. Supp. 660, 665 (D.N.J. 1975).
61. Id. at 663.
62. Id.
63. Id. at 664.
64. Id.
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cumstantial evidence that showed the pregnancy test kit manufacturer in-
tended to market or promote the product for that purpose.  Or, maybe
there was lack of proximity between the explicit use of the pregnancy test
kit, which is merely checking for pregnancy, and the implied intended use
for prevention of health risks.
As can be seen from the two decisions, a diagnostic method could be
categorized as a “drug” under the FDCA regardless of whether it involves
direct contact with the human body—the crucial point is how broadly the
definition is interpreted.  However, the District of New Jersey’s distinction,
that the pregnancy kit does not provide an assessment of life-and-death
risks, bolsters the FDA’s interpretation that the GE mosquito is not a drug
for humans.  Even though the purpose of the GE mosquito project is to
save lives by preventing diseases, the project is not dealing with matters as
urgent as checking the antibiotic sensitivity of patients who have already
contracted serious diseases and whose lives depend on the results of the
sensitivity test.  That lack of urgency might only provide a weak proximity
link between the release of the GE mosquitoes and the eventual intended
consequences of the release—to prevent human disease.
Exactly how much urgency is necessary for a product to qualify as a
drug under the “prevention” clause of the FDCA has not been settled.
Therefore, although Oxitec announced that the intended use of the GE
mosquitoes is to prevent human diseases, there might be lack of proximity
between the release of the mosquitoes and the intended consequences of
preventing humans’ exposure to diseases to say for certain that the FDA’s
interpretation of the statute regarding the project is arbitrary and capricious
under the Administrative Procedure Act.65
B. FDA Fails to Account for Self-Acting Nature of Mosquitoes
Once the GE mosquitoes are released into the wild, they behave based
on their own survival instinct, independent from the inserted gene.  The
self-limiting gene is not able to do its job unless the mosquito survives in
the wild, pursues mating, and produces offspring.  Not only is the success
of Oxitec’s technology dependent on the function of the self-limiting gene,
but it is also dependent on the capability of the lab-grown mosquitoes to
survive and mate in the wild.  In this sense, the GE mosquitoes are “self-
acting.”
The self-acting GE mosquitoes, like the self-limiting genes inside them
discussed in Section II.A. above, have two intended uses: decreasing the
overall mosquito population and limiting human exposure to disease trans-
65. 5 U.S.C. § 706 (1966).
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mitted by the mosquito.66  The mosquitoes themselves are likely “drugs”
under Section 201(g)(1)(C) of the FDCA because the decrease of the mos-
quito population is achieved by passing the self-limiting gene to offspring,
which in turn affects the “function of the body” of the offspring by killing
it.67  Under this interpretation, the mosquito itself should be regulated
under a separate layer of regulation from the self-limiting gene, or a new
regulation scheme would have to be devised to both regulate the self-limit-
ing gene and the mosquito itself simultaneously as a “new animal drug.”
However, a potential quandary that arises from the authorizing statute
is that the self-limiting gene is a “drug” under the definition of the word in
the statute, but the mosquito itself is not a “drug.”  This confusion becomes
especially important if we are to recognize the self-acting characteristics of
GE mosquitoes.  If we assume that the mosquito is a living animal that acts
separately and independently from the self-limiting gene inside, then it is
improper to assume that regulating the gene as a drug has the same effects
as regulating the mosquito that contains the gene.
Comparing the GE mosquito technology to traditional drugs, the cur-
rent regulation might treat the self-limiting gene as the chemical compound
and the mosquito as the capsule, syringe, or other medium in which the
drug is transported and delivered.  The biggest failure of this analogy comes
from the fact that a capsule or a syringe does not have self-acting character-
istics, while a living, autonomous mosquito does.  The current regulatory
scheme does not account for this failure of analogy.
The closest thing to an explanation that the FDA has given regarding
this issue is on its website’s Q&A page.  There, the FDA states that “GE
animals are not drugs” and explains that:
[The FDCA] defines a new animal drug as “an article (other than
food) intended to affect the structure or any function of the body
of . . . animals.”  A recombinant DNA (rDNA) construct intended
to affect the structure or function of an animal meets the definition
of a new animal drug, regardless of whether the resulting GE ani-
mals are intended for food, or to produce pharmaceuticals or any
other substances.  As a short hand we sometimes refer to regulation
of the article in such GE animals as regulation of the GE animal.68
66. Oxitec, Overview, supra note 6. R
67. See 21 U.S.C. § 321(g)(1)(C) (2012).
68. FDA, General Q&A, ANIMAL & VETERINARY, http://www.fda.gov/AnimalVeterinary/
DevelopmentApprovalProcess/GeneticEngineering/GeneticallyEngineeredAnimals/ucm1136
05.htm (last updated Nov. 19, 2015).
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Going back to the analogy to traditional drugs, the FDA’s explanation es-
sentially means that the compound inside the capsule is a drug while the
capsule itself is not a drug, and the regulation of the compound inside the
capsule is sufficient for the regulation of the capsule.
Perhaps the FDA made this statement because the agency wanted to
make clear that a separate process is needed to approve additional products
derived from GE animals that are intended to affect humans or other ani-
mals.  For example, one of the intended purposes of creating GE animals is
“to produce products intended for human therapeutic use (e.g., pharmaceu-
tical products or tissues for transplantation; these GE animals are some-
times referred to as ‘biopharm’ animals).”69  Instead of allowing the
commercial use of therapeutics derived from GE animals by getting an ap-
proval just for the rDNA construct inside the GE animal, the FDA proba-
bly intended such producers to file a separate application for the approval of
those therapeutics.70  Applying it to the compound and capsule analogy
above, the FDA might have wanted to say that approval of the compound
inside the capsule does not mean that any other compound produced by the
capsule itself is also approved.
However, this possible interpretation of the FDA’s intention fails be-
cause no guidance is given for situations where the GE animal itself is used
as a drug.  The Center for Veterinary Medicine (CVM) department of the
FDA, the GE animal application oversight body, offers six intended pur-
poses for creating GE animals:
(1) to enhance production or food quality traits (e.g., pigs with less
environmentally deleterious wastes, faster growing fish); (2) to im-
prove animal health (e.g., disease resistance); (3) to produce prod-
ucts intended for human therapeutic use (e.g., pharmaceutical
products or tissues for transplantation; these GE animals are some-
times referred to as “biopharm” animals); (4) to enrich or enhance
the animals’ interactions with humans (e.g., hypo-allergenic pets);
(5) to develop animal models for human diseases (e.g., pigs as mod-
els for cardiovascular diseases); and (6) to produce industrial or
consumer products (e.g., fibers for multiple uses).71
None of these intended purposes include creating a GE animal to kill other
animals or to mitigate humans’ exposure to diseases, nor do any of the other
69. FDA GUIDANCE, supra note 42, at 4.
70. Id.
71. FDA, GUIDANCE FOR INDUSTRY: REGULATION OF GENETICALLY ENGINEERED ANIMALS CON-
TAINING HERITABLE RECOMBINANT DNA CONSTRUCTS (2015).
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guidelines published by the FDA address the possible use of a GE animal as
a drug for humans or other animals.72
In fact, a double regulatory scheme, in which the rDNA inserted into a
GE animal is regulated separately from a product derived from the GE
animal, is already in place for any use of the GE animal currently conceived
by the FDA that comes in contact with humans.  In a guidance document
for therapeutic products for human use derived from transgenic animals, the
FDA states that “[t]he majority of products for human use derived from
transgenic animals and intended for diagnostic, preventative or therapeutic
purposes will be regulated as biological products.”73
For example, in the case of xenotransplantation applications of GE ani-
mals, in which live organs, tissues, or cells from the GE animal are trans-
planted into the human body, the FDA “will regulate most
xenotransplantation products as biological products. CBER regulates bio-
logical products, including cellular therapies, under authority of section 351
of the PHS Act (42 U.S.C. 262), and the [FDCA] (21 U.S.C. 321 et
seq.).”74
Meanwhile, no such double regulatory scheme exists for GE animals
that are self-acting and come in direct contact with humans.  It is possible
that the FDA did not foresee that a GE animal could be used as a drug by
itself.  However, the lack of explicit guidance by a government agency re-
garding a particular subject matter does not mean that the subject matter
has not been addressed by a federal statute.  As such, the next section re-
72. See FDA CENTER FOR BIOLOGICS EVALUATION AND RESEARCH [CBER], POINTS TO CON-
SIDER IN THE MANUFACTURE AND TESTING OF THERAPEUTIC PRODUCTS FOR HUMAN USE DERIVED FROM
TRANSGENIC ANIMALS (1995) [hereinafter CBER, POINTS TO CONSIDER]; U.S. DEPT. OF HEALTH
AND HUMAN SERVICES & CBER, ANIMAL, PRODUCT, PRECLINICAL, AND CLINICAL ISSUES CONCERNING
THE USE OF XENOTRANSPLANTATION PRODUCTS IN HUMANS (2003).
73. CBER, POINTS TO CONSIDER, supra note 72, at 2. R
Biological products, including cellular therapies, are regulated by CBER under
authority of the Public Health Service Act (42 U.S.C., Sec. 201 et seq.) and the
Federal Food, Drug, and Cosmetic Act (21 U.S.C., Sec. 301 et seq.). The regula-
tions are found at Title 21 of the Code of Federal Regulations (21 CFR). Thera-
peutic products for use in humans not regulated as biologics may be regulated by
the Center for Drug Evaluation and Research (CDER) or the Center for Devices
and Radiological Health (CDRH). In addition, FDA’s Center for Veterinary
Medicine (CVM) and Center for Food Safety and Applied Nutrition (CFSAN)
and the United States Department of Agriculture (USDA) have regulatory re-
sponsibility for veterinary and food safety issues associated with final products and
the use of transgenic animals.
Id. at 2–3.
74. CBER, GUIDANCE FOR INDUSTRY: SOURCE ANIMAL, PRODUCT, PRECLINICAL, AND CLINICAL
ISSUES CONCERNING THE USE OF XENOTRANSPLANTATION PRODUCTS IN HUMANS 7 (2003).
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views the FDCA in order to determine whether the FDA’s ignorance of the
self-acting nature of the GE animals was reasonable.
C. GE Mosquitoes Might Qualify as Extralabel Use
If it is indeed the case that the GE mosquito is separable into two
different products, the self-limiting gene and the living organism itself,
then the GE mosquito should pass two sets of regulations, one for each
product, or alternatively, just one regulation that addresses the safety and
efficacy of both products.
The current requirements for a new animal drug application (NADA)
are listed in Section 512(b)(1) of the FDCA75 and more thoroughly ex-
plained in the FDA’s regulations.76  Although the FDA, in its Guidance for
Industry document, asserts that the intended use of the resulting GE
animal should be provided in the application,77 no such language can actu-
ally be found in its regulation.78  The Guidance for Industry document
might have a non-binding effect on the NADA applicant, evidenced by the
“Contains Non-Binding Recommendations” disclaimer clearly marked on
the top of every page of the document.79  Taken literally, no binding re-
quirement exists for the GE animal producer to separately reveal the in-
tended purpose of the GE animal itself.  Moreover, neither the FDA
regulation nor the guidance document provides requirements for labeling or
safety and efficacy directed towards the GE animal itself; the requirements
are only directed towards the “new animal drug,” which is the self-limiting
gene in the case of the GE mosquitoes.80  In other words, only the labeling,
safety, and efficacy requirements of the self-limiting gene have to be satis-
fied, and no such information has to be provided regarding the GE mos-
quito itself in order to get an approval for the GE mosquitoes.
If it is assumed that because of the lack of extra layer of regulation on
the GE mosquitoes, Oxitec failed to describe on its label for the GE mos-
quitoes that the mosquitoes are intended to kill other mosquitoes or to miti-
75. 21 U.S.C. § 360b (2012).
76. 21 C.F.R. § 514.1 (2016).
77. FDA GUIDANCE, supra note 42, at 14.
78. 21 C.F.R. § 514.1(b).
79. If the guidance document is considered to be merely an interpretive rule, then the
court might find that it is binding despite the lack of notice and comment rulemaking. Perez
v. Mortg. Bankers Ass’n, 135 S. Ct. 1199, 1206 (2015).  On the other hand, if a document
characterized by an agency as a policy or guidance document in fact imposes new and sub-
stantive requirements on the regulated community, that document might require notice and
comment rulemaking. Appalachian Power Co. v. EPA, 208 F.3d 1015, 1024 (D.C. Cir.
2000).
80. FDA GUIDANCE, supra note 42, at 14–20; 21 C.F.R. § 514.1(b). R
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gate humans’ exposure to disease, then Oxitec is making promotional
statements both on its website and through mass media that are beyond the
scope of its label.  For drugs intended for human therapeutic use, some of
the largest settlements for civil and criminal allegations have involved issues
of pharmaceutical companies marketing their drugs for uses other than the
ones approved by the FDA.81  In animal drugs, a concept similar to the off-
label use would be “extralabel use,” a term which was introduced in the
Animal Medicinal Drug Use Clarification Act (AMDUCA) of 1994.82
Under the FDA regulations “extralabel use” is defined as:
[A]ctual use or intended use of a drug in an animal in a manner
that is not in accordance with the approved labeling. This includes,
but is not limited to, use in species not listed in the labeling, use
for indications (disease or other conditions) not listed in the label-
ing, use at dosage levels, frequencies, or routes of administration
other than those stated in the labeling, and deviation from the la-
beled withdrawal time based on these different uses.83
The language of the regulation suggests that only the use or intended
use “in an animal” is considered as an extralabel use that is forbidden by the
regulation.  Killing other mosquitoes by breeding and giving birth to off-
spring could arguably be a use “in an animal” since the self-limiting gene is
inherited “in” the offspring.  Therefore, it could be argued that the self-
limiting gene affecting the parent mosquito is an approved use of the new
animal drug, but the mosquito itself affecting the offspring is an extralabel
use.
Alternatively, it could be argued that the examples given in the second
sentence of the definition only refer to drugs that are administrable by a
veterinarian—animal drugs in a traditional sense.  However, the rDNA con-
structs that are not animal drugs in a traditional sense are not explicitly
mentioned in the regulation as examples of drugs.  Many requirements de-
lineated in the FDA’s regulation only consider chemical compound drugs,
as evidenced by NADA requirements that explicitly ask the applicant to
provide information on the “chemistry”84 and “components and composi-
tion” of chemicals.85  Therefore, if the FDA decided to apply its regulations
to rDNA, then the examples of possible extralabel uses explicitly mentioned
81. See, e.g., Gardiner Harris, Pfizer Pays $2.3 Billion to Settle Marketing Case, N.Y.
TIMES (Sept. 2, 2009), http://www.nytimes.com/2009/09/03/business/03health.html.
82. 21 USC § 360b(a)(4)–(5) (2012); 21 C.F.R. pt. 530 (2016).
83. 21 C.F.R. § 530.3(a).
84. 21 C.F.R. § 514.1(b)(2)(i).
85. 21 CFR § 514.1(b)(4).
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in its regulation should not forbid the agency from applying the extralabel
regulation to an animal itself as long as its definition is met.
However, even if Oxitec’s promotional activities regarding the intended
use of the GE mosquito itself qualify as extralabel use, the Second Circuit
has recently decided that “the government cannot prosecute pharmaceutical
manufacturers and their representatives under the FDCA for speech pro-
moting the lawful, off-label use of an FDA-approved drug,”86 which implies
that Oxitec at least has a First Amendment defense if the mosquitoes are
indeed effective at killing other mosquitoes.
Another potential problem stemming from the extralabel use of the GE
mosquito is the AMDUCA’s mention of “residue.”  The statute states that
any extralabel use which results in residues that “present a risk to the public
health” should not be permitted and that “[s]afe levels may be estab-
lished . . . by regulation or order.”87  A definition of “residue” is not given in
the FDCA.  Instead, the word is used in the context of “pesticide chemical
residue”88 and food additives.89
If there is no case of extralabel use, the FDA guidance only requires
that a “NADA include method(s) and data to enable determination of resi-
dues of the new animal drug in food-producing animals, except when data
or other adequate information establish that it is not reasonable to expect
the new animal drug to become a component of food at concentrations con-
sidered unsafe.”90  Restricting the requirement for measurement of residue
just to “food-producing animals” is not consistent with the purpose of the
FDCA that requires all approved drugs to be safe to public health.  Since
the GE mosquitoes would not be used as food for humans, it is likely that
the FDA will not require Oxitec to present data on how the rDNA residue
can be measured and assessed, both in the environment and in other animals
and humans, unless an accusation of extralabel use is made.
Mosquitoes are an important source of food for many animals in the
environment, and even if humans do not directly consume mosquitoes, they
could be exposed to the residue of the self-limiting gene.91  Therefore, not
86. United States v. Caronia, 703 F.3d 149, 169 (2d Cir. 2012).
87. 21 U.S.C. § 360b(a)(4)(B).
88. See 21 U.S.C. § 321(q)(2) (2012).
89. See 21 U.S.C. § 348(c)(3) (2012).
90. FDA GUIDANCE, supra note 42, at 18. R
91. Generally, there is lack of proof on whether female modified mosquitoes are capa-
ble of spreading genetic material through bites or whether modified genetic materials would
remain in the environment after the mosquitoes serve their purpose.  As stated in Section I
of this Note, the safety of GE mosquitoes is a scientific inquiry.  This section of the Note is
only addressing the gap in regulations that fail to require such scientific study assessing
whether the technology is safe. See Helen Wallace, Genetically Modified Mosquitoes Have Few
Proven Benefits, Too Many Risks, N.Y. TIMES (Feb. 23, 2015), http://www.nytimes.com/room-
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only should the issue of residue be within the scope of the National Envi-
ronmental Policy Act (NEPA), which requires the FDA to review environ-
mental risks of every NADA,92 the issue should also be within the purview
of the FDCA.
The cause of those legislative drafting gaps might be that neither Con-
gress nor the FDA was able to foresee the necessity of addressing the self-
acting nature of GE animals.  In other words, the residue problem would
not have surfaced had the GE mosquitoes been kept in the lab, but once
they go out into the wild as self-acting organisms and start interacting with
the environment, problems not adequately addressed by the statute such as
extralabel use and residue occur.
In summary, the GE mosquito project does not fit within the current
FDCA because it is mischaracterized as an “animal drug.”  That begs the
question why other government agencies such as the U.S. Department of
Agriculture (USDA) have failed to assert their authority on the jurisdiction
of GE mosquitoes, despite their authoritative roles on the regulation of
other GE animals.  Therefore, it is necessary to explore the overall interac-
tion of different government agencies in the subject matter of GE animals.
III. FDA SHOULD NOT BE THE ONLY AGENCY WITH
JURISDICTION OVER GE MOSQUITOES
As discussed in Section II, the GE mosquito technology is mis-
characterized under the FDA’s current jurisdiction.  This poor fit begs the
exploration of other existing options for regulating the GE mosquitoes.
The USDA asserting jurisdiction over GE mosquitoes might have been
more consistent with its past assertions of jurisdiction over GE insects.
However, the USDA voluntarily abrogated its jurisdiction on GE mos-
quitoes, which is questionable given its extensive experience dealing with
GE insects.  The unclear assertion of jurisdiction by the FDA could give
rise to a lawsuit like the one challenging the FDA’s authority to regulate the
GE salmon.93
fordebate/2015/02/23/can-genetically-modified-mosquitoes-eliminate-dengue-fever/geneti-
cally-modified-mosquitoes-have-few-proven-benefits-too-many-risks; Jennifer Kay,
Genetically Modified Mosquitoes No Danger to Humans or Environment, FDA Says, WASH. POST
(Mar. 12, 2016), https://www.washingtonpost.com/politics/genetically-modified-mosquitoes-
no-danger-to-humans-or-environment-fda-says/2016/03/12/bd55dc52-e889-11e5-b0fd-073d59
30a7b7_story.html?utm_term=.0ddb2ca49d2e.
92. FDA, supra note 48.
93. See, e.g., Complaint ¶ 11, Institute for Fisheries Resources v. Burwell, 2016 WL
4529517 (Aug. 30, 2016 N.D. Cal.) (No. 3:16-cv-01574), http://www.biologicaldiversity.org/
campaigns/ge_seafood/pdfs/2016-3-30-dkt-1-pls-complaint_94703.pdf.  In this case, the
plaintiffs allege that the FDA lacked explicit “statutory authority to regulate GE animals as a
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A. Coordinated Framework Is Not Intuitive
The Coordinated Framework for Regulation of Biotechnology was an-
nounced in 1986 and updated in 1992 by the Executive Office of the Presi-
dent, Office of Science and Technology Policy (OSTP) to outline the
federal agencies’ policies towards regulation of products derived from bio-
technology including genetic engineering.94  The policy states that
“[e]xisting statutes provide a basic network of agency jurisdiction over both
research and products; this network forms the basis of this coordinated
framework and helps assure reasonable safeguards for the public.”95  Rather
than adding any new rationale to the logic of why GE animals have to be
categorized into “animal drug,” the policy merely reiterates the regulatory
jurisdictions asserted by three government agencies, the USDA, Environ-
mental Protection Agency (EPA), and FDA.  In other words, the policy
stated that no new regulations are necessary for products derived from ge-
netic engineering and that interpretation of the existing statues is enough to
accommodate the new technologies.
This is a reasonable policy considering the fact that it comes from the
executive branch rather than from the judicial or legislative branches.  How-
ever, the framework is outdated.  Even the Executive Office of the Presi-
dent recognized the problem and issued a memorandum titled
“Modernizing the Regulatory System for Biotechnology Products” on July
2, 2015.96  The memorandum created a working group that was tasked with
clarifying “the roles that each agency plays for different product areas, par-
ticularly for those product areas that fall within the responsibility of multi-
ple agencies, and how those roles relate to each other in the course of a
regulatory assessment.”97
The result of this effort came 14 months later in the September 2016
proposed document titled “Modernizing the Regulatory System for Bio-
technology Products: An Update to the Coordinated Framework for the
‘new animal drug’” and Congress did not intend for FDA to have authority to regulate GE
animals because they require “different expertise, analyses, and regulation that were contem-
plated when Congress enacted the FFDCA.” Id.
94. See generally Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg.
23302, 23302 (Jun. 26 1986), http://www.aphis.usda.gov/brs/fedregister/coordinated_frame
work.pdf.
95. Id.
96. Executive Office of the President, Memorandum for Head of Food and Drug Adminis-
tration, Environmental Protection Agency, and Department of Agriculture: Modernizing the Regula-
tory System for Biotechnology Products (July 2, 2015), https://www.epa.gov/sites/production/
files/2016-12/documents/modernizing_the_reg_system_for_biotech_products_memo_final
.pdf [hereinafter Modernizing the Regulatory System for Biotechnology Products].
97. Id. at 3.
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Regulation of Biotechnology.”98  However, the updated framework does
nothing to change the way GE mosquitoes are regulated.  It simply states
that the “FDA regulates GE animals under the new animal drug provisions
of the FD&C Act and FDA’s implementing regulations” without offering
any new insight into why the FDA should have the sole authority over these
animals.99  Instead, it lauds the FDA’s Guidance for Industry document
published in 2015 by stating that the guidance “clarifies FDA’s approach to
regulating GE animals and provides recommendations to help producers of
GE animals meet their responsibilities under the law.”100
Perhaps the biggest problem with the framework is that it is not intui-
tive.  Because one of the two main purposes of releasing GE mosquitoes is
to reduce the population of mosquitoes,101 one might intuitively think that
the USDA and the EPA should also have jurisdiction on the GE mos-
quitoes due to their agency expertise on insects and the environment, re-
spectively.  In fact, this was the intuition that the government agencies
initially had when, in 2009, Oxitec started asking which federal agency it
needed approval from regarding the GE mosquito project.  The USDA ini-
tially claimed jurisdiction over the project, so in March 2010, Oxitec filed
an application for importation of GE mosquitoes into the U.S. from the
U.K.102  The USDA rescinded its jurisdiction over the GE mosquitoes after
an 18-month delay.103  It has been reported that the USDA avoided jurisdic-
tion in October 2011 by determining that the project poses no threat to
animal health.104
The FDA asserts jurisdiction because the GE mosquitoes affect the
structure and function of other mosquitoes in the wild; the USDA’s ratio-
nale for declining jurisdiction is that those effects do not amount to a threat
to animal health.  That rationale is not intuitive.  Also, even if it is con-
ceded that the other main purpose of the project—preventing human expo-
sure to tropical disease—is why the FDA should have jurisdiction, the
veterinary department of the FDA has jurisdiction, rather than the human
health department.
98. Executive Office of the President, Modernizing the Regulatory System for Biotechnology
Products: An Update to the Coordinated Framework for the Regulation of Biotechnology (proposed
Sept. 2016), https://www.epa.gov/sites/production/files/2017-01/documents/2017_coordi-
nated_framework_update.pdf.
99. Id. at 16.
100. Id. at 17.
101. Oxitec, Overview, supra note 6. R
102. Joe Palca, Biotech Firms Caught in Regulatory No Man’s Land, NPR (Jan. 3, 2014
12:01 AM), http://www.npr.org/2012/01/02/144330629/biotech-firms-caught-in-regulatory-
no-mans-land.
103. Id.
104. Friends of the Earth, supra note 49. R
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All of this confusion happened even after the FDA came out with the
first version of the Guidance for Industry document in June 2015, which
stated that the GE animals would be regulated under the FDCA as an
“animal drug.”105  This confusion indicates that the GE mosquito project
fits awkwardly in the current Coordinated Framework and demonstrates
just how farfetched the interpretation of the current statutes is to justify the
FDA’s sole jurisdiction over the project.
The Coordinated Framework allows different government agencies to
assert jurisdiction on the same project.  For example, the FDA is the lead
agency and the Food Safety and Inspection Service (FSIS), which is an
agency in the USDA, is the supporting agency for the approval of foods and
food additives made from genetic engineering.106  Also, the EPA is the lead
agency and the Animal and Plant Health Inspection Services (APHIS),
which is also an agency in the USDA, is the supporting agency for the
approval of pesticide microorganisms released in the environment.107
Of course, there is no doubt that the FDA will consult with the USDA
and EPA when making decisions regarding the approval of the GE mos-
quito project because of the NEPA requirements regarding premarketing
approvals of FDA-regulated products.108  However, it remains to be seen
whether the counterintuitive policy of the Coordinated Framework allowing
FDA to be the sole decision maker on the GE mosquito project has any
bearing on the authority of the USDA and EPA on the project.
B. FDA’s Assertion of Jurisdiction Might Be Inconsistent
Even if the framework is counter-intuitive, judicial action is not likely
to overturn the FDA’s assertion of jurisdiction over the GE mosquitoes
because there is lack of any clear statutory act giving sole authority to any
other particular government agency over the GE mosquito project.  Also,
the deference given by the judicial body to agency interpretation of statutes
might make the FDA’s assertion of jurisdiction stronger in the face of a
judicial challenge.  The Supreme Court has specifically stated that legisla-
tion “such as the Food, Drug, and Cosmetic Act is to be given a liberal
construction consistent with the Act’s overriding purpose to protect the
public health.”109
105. See supra Section II.A. and accompanying notes.
106. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302,
23,304 (Jun. 26 1986), http://www.aphis.usda.gov/brs/fedregister/coordinated_framework
.pdf.
107. Id.
108. 21 C.F.R. pt. 25 (2016).
109. United States v. Article of Drug Bacto-Unidisk, 394 U.S. 784, 798 (1969).
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The remaining question is whether the FDA’s past assertions of juris-
diction over GE animals have been consistent.  The consistency of the
FDA’s assertion of jurisdiction was deemed important when the Eighth
Circuit concluded that, although a literal reading of the definition of “drug”
under the FDCA included animal biologics, the FDA lacked prior enforce-
ment activity on them and therefore, animal biologics are not “drugs” under
the FDCA.110
At first glance, the USDA seems to have been the major player in regu-
lating GE animals.  The USDA in 2008 released the world’s first Environ-
mental Impact Statement (EIS) on the GE fruit fly and pink bollworm in
the APHIS plant pest control program.111  This EIS has been widely used
as the basis for regulatory approvals of other genetically engineered insects.
For example, the USDA had sole jurisdiction over GE diamondback
moths.112  These moths were also developed and produced by Oxitec using
the same concept of self-limiting genes.113  They have since been released as
a part of an outdoor field trial in New York state.114  Meanwhile, the first
and only approval of GE animals made by the FDA under the FDCA was
for AquAdvantage Salmon, an “[a]tlantic salmon that reaches market size
more quickly than non-GE farm-raised Atlantic salmon.”115
These past GE animal projects do not provide conclusive evidence of
whether the FDA’s assertion of jurisdiction has been consistent.  The GE
fruit fly, pink bollworm, and diamondback moths are regarded as pests,
while the AquAdvantage salmon is a food product.  Unlike GE mosquitoes,
production of salmon is not intended to affect the public health.  However,
one important point is that the self-limiting gene for the GE moth did not
have to go through FDA approval.
110. See Grand Laboratories, Inc. v. Harris, 644 F.2d 729, 734–35 (1981).
111. See USDA, USE OF GENETICALLY ENGINEERED FRUIT FLY AND PINK BOLLWORM IN APHIS
PLANT PEST CONTROL PROGRAMS (Oct. 2008), http://www.aphis.usda.gov/plant_health/ea/
downloads/eis-gen-pbw-ff.pdf.
112. USDA, Withdrawal of an EA for Field Release of GE Diamondback Moths, OUR FOCUS,
https://www.aphis.usda.gov/aphis/ourfocus/biotechnology/sa_environmental_documents/
sa_environmental_assessments/diamondback-moth-permit-withdrawal (last modified Nov. 7,
2016).
113. Oxitec, Diamondback Moth, AGRICULTURE, http://www.oxitec.com/agriculture/our-
products/diamond-back-moth/ (last visited Dec. 22, 2016).
114. Christina Sarich, Genetically Modified Moths Released in New York, NATURAL SOCIETY
(June 19, 2016), http://naturalsociety.com/outrage-oxitecs-gm-moths-are-released-in-new-
york.
115. Press Release, FDA, FDA Takes Several Actions Involving Genetically Engineered
Plants and Animals for Food (Nov. 19, 2016), http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm473249.htm.
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In the Environmental Assessment of the GE moth project released by
the USDA in May 2014, the USDA tried to explain why the FDA did not
partake in the assertion of jurisdiction over the project:
FDA uses what is termed a consultation process to ensure that
human food and animal feed safety issues or other regulatory issues
(e.g., labeling) are resolved prior to commercial distribution of
bioengineered food.  The permit applicant did not undergo this
voluntary consultation because GE diamondback moth is not antic-
ipated to yield food or feed.116
This contradicts FDA’s position regarding the GE mosquito, which is also
not anticipated to yield food or feed.  However, it is not clear that a court
would conclude that such inconsistency amounts to arbitrary and capricious
agency action.
C. The Lawsuit Over GE Salmon Suggests That Potential
Challengers Might Face Hurdles in Proving Standing
Not everyone was convinced that the GE salmon approved by the FDA
was best suited for FDA jurisdiction.  In March 2016, nearly a dozen envi-
ronmental groups filed a complaint in the Northern District of California
over the FDA’s approval of the GE salmon.117  The plaintiffs first alleged
that the FDA lacks statutory authority to regulate GE animals as a “new
animal drug” under the FDCA; that challenge was discussed above in Sec-
tion II.118
Next, the plaintiffs alleged that FDA did not fully consider or disclose
the environmental and other risks of allowing this project and that the stat-
ute does not grant the FDA authority to assert jurisdiction over the GE
salmon application.119  The complaint alleged that the environmental assess-
ment (EA) and the finding of no significant impact (FONSI) failed to “dis-
cuss or adequately evaluate myriad scientific questions regarding the risk of
significant and irreversible environmental, ecological, and intertwined so-
cioeconomic harms related to the production, commercialization, and
proliferation of AquaBounty’s GE fish.”120  It further claimed that the FDA
ignored the threats cited by expert scientists that include the possibility of
GE salmon escaping from the facilities where they are manufactured or
116. USDA, PROPOSAL TO PERMIT THE FIELD RELEASE OF GENETICALLY ENGINEERED DIAMOND-
BACK MOTH IN NEW YORK 7 (2014).
117. Complaint, supra note 93, ¶ 1. R
118. Id. ¶ 11.
119. Id. ¶ 7–9.
120. Id. ¶ 8.
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grown and interbreeding with wild endangered salmon, resulting in compe-
tition with them for food and space, or passing infectious diseases.121  That
potential threat exists because of the “self-acting” nature of the GE salmon
like that of the GE mosquito discussed in Section II.B. above.122  Such
inadequate studies by the FDA, the complaint claims, “are the result of
FDA’s failure to take the legally required ‘hard look’” and are thus arbi-
trary, capricious, and contrary to APA, National Environmental Policy Act
(NEPA), ESA, and FDA Amendments Act.123
Finally, the complaint added that “even if FDA had the authority to
issue the GE Animal Guidance, the guidance itself fails to explain how
FDA will substantively incorporate important environmental considerations
into its assessment of safety and effectiveness as a part of the review and
approval of GE animals.”124  In other words, FDA failed to incorporate
environmental risks as a part of its statutory “safety” evaluation.
The GE salmon complaint does not allege that the product is unsafe for
human consumption—it only focuses on the potential environmental risks
that might arise if the GE salmon interact with the natural population.125
Natural mosquitoes, on the other hand, are less likely to be seen as subjects
worth much protection.  Unlike the natural population of salmon, mos-
quitoes are mostly seen as annoyances and disease-transmitters.  Moreover,
the scientific community thinks that the eradication of mosquitoes would
not have any serious consequences for the ecosystem.126
Here, proving standing would be the biggest hurdle for the potential
challengers of the GE mosquito project.127  Proving injury in fact for the
GE salmon challengers might be easier because bigger GE salmon have
survival advantages over the natural population.128  With the scientific com-
munity approving the eradication of the mosquito population, the challeng-
ers of the GE mosquito project might have a more difficult time asserting
that the GE mosquito project is a threat to the environment.  Also, Oxitec
121. Id.
122. See supra Section II.A. and accompanying notes.
123. Complaint ¶ 9, Institute for Fisheries Resources v. Burwell, 2016 WL 4529517
(Aug. 30, 2016 N.D. Cal.) (No. 3:16-cv-01574).
124. Id. ¶ 12.
125. See id.
126. Janet Fang, A World Without Mosquitos, 466 NATURE 432, 434 (2010).
127. Standing requires the plaintiff to show an injury in fact, causation and redres-
sability. Lujan v. Defenders of Wildlife, 504 U.S. 555, 560–61 (1992).  Also, the GE salmon
lawsuit was dismissed in August 2016 without the court addressing the question of standing.
Therefore, the question of standing in the case is only speculative at this point.
128. See e.g., Fredrik Sundstro¨m & Robert H. Devlin, Increased Intrinsic Growth Rate is
Advantageous Even Under Ecologically Stressful Conditions in Coho Salmon, 25 EVOLUTIONARY
ECOLOGY 447 (2011).
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seems confident that the GE mosquito is not a threat to human health.129
Without any substantive evidence pointing otherwise, proving injury in fact
as an element of demonstrating standing might be difficult.
IV. REGULATORY LESSONS CAN BE LEARNED FROM ABROAD
Some residents of Key West might be relieved to know that a few other
countries have already released Oxitec’s GE mosquitoes without any report
of negative effects.130  In 2009 and 2010, 3.3 million mosquitoes were re-
leased in the Cayman Islands; 3 million in northeastern Brazil in 2011; and
6,000 in Malaysia in 2010.131  The troublesome part of these releases is that
no international regulation specific to the release of GE mosquitoes has
been developed.132  However, some countries, such as Mexico, have devel-
oped regulatory bodies tailored specifically for GE insects, including Ox-
itec’s mosquitoes.133
A. International Regulation Introduces the “Self-Acting” Concept
The World Health Organization (WHO) has published a guidance doc-
ument for testing GE mosquitoes, but the document merely describes the
current regulatory framework and gives vague recommendations of what the
regulatory framework should encompass without any enforcement effect.134
The guidance recognizes that “[e]ach country has its own sovereign regula-
tory process, but overarching international agreements or treaties also may
be relevant” without much detail.135
The Cartagena Protocol on Biosafety to the Convention on Biological
Diversity is the closest thing the international community can rely on in
judging whether the release of the mosquitoes would comply with interna-
tional regulatory standards.136  However, the protocol was mostly designed
to oversee international trade of genetically modified agricultural products,
129. Oxitec, Safety & Sustainability, OUR SOLUTION, http://www.oxitec.com/our-solution/
safety-sustainability/ (last visited Dec. 22, 2016).
130. See Lim Li Ching, GM Mosquitoes: Flying Through the Regulatory Gaps, GENEWATCH,
http://www.councilforresponsiblegenetics.org/genewatch/GeneWatchPage.aspx?pageId=421
(last visited Dec. 5, 2016).
131. Id.
132. See id.
133. See infra Section IV.B.
134. WHO, GUIDANCE FRAMEWORK FOR TESTING OF GENETICALLY MODIFIED MOSQUITOES
(2014), http://apps.who.int/iris/bitstream/10665/127889/1/9789241507486_eng.pdf?ua=1.
135. Id. at xxv.
136. See Graciela R. Ostera & Lawrence O. Gostin, Biosafety Concerns Involving Geneti-
cally Modified Mosquitoes to Combat Malaria and Dengue in Developing Countries, 305 JAMA
930, 931 (2011).
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so its application to GE mosquitoes was questioned from the beginning.137
In an attempt to resolve this problem, the Ad Hoc Technical Expert Group
on Risk Assessment and Risk Management to the Conference of the Parties
attempted to provide specific guidelines for GE mosquitoes in Nagoya, Ja-
pan, in October 2010.138  However, the group faced criticism that they did
not address significant technical issues.139  The U.S. is not a party to the
Cartagena Protocol, which makes it unenforceable in the United States.140
However, an important aspect of the WHO’s guidance is its indirect
recognition of the “self-acting” nature of the GE mosquito technology dis-
cussed in Section II.B.  The WHO does not recognize the self-acting char-
acteristics directly, but does indirectly by articulating the concept of a “self-
sustaining” organism.141  “Self-sustaining” is defined by the WHO as an
approach “where the heritable modification is spread and maintained indefi-
nitely through the target population.”142  Even though sterile insect tech-
niques such as Oxitec’s technology are categorized as self-limiting instead of
self-sustaining by the WHO,143 the mosquitoes released into the wild have
at least transient self-sustaining characteristics until sufficient time passes
for the elimination of the population through breeding and production of
offspring.  Because of this transient self-sustaining characteristic, concerns
arise as to the movement of these mosquitoes, particularly regarding their
transboundary movements.144  In other words, international regulatory ef-
forts to address the transboundary movements of the mosquitoes after their
release into the wild are important in some cases because humans cannot
control the spread or migration of GE mosquitoes after release.
Even though the release of mosquitoes in Key West might not require
an international effort because the region is separated from any other coun-
try by a body of water, roads and boats still connect the region to the main-
land U.S.  The discussion of self-acting characteristics of the mosquitoes is
still relevant domestically.  Additionally, although the self-acting concept
was only indirectly inferred from the WHO guidelines and did not play an
important role in the discussions for international regulations, the concept
137. See id.
138. Id.
139. Id.
140. List of Parties: Cartagena Protocol, CONVENTION ON BIOLOGICAL DIVERSITY, https://www
.cbd.int/information/parties.shtml#tab=1 (last visited Dec. 22, 2016).
141. WHO, GUIDANCE FRAMEWORK FOR TESTING OF GENETICALLY MODIFIED MOSQUITOES,
supra note 134, at 4 (discussing “self-sustaining” as a category recognizing a GE mosquitoes R
ability to persist following release).
142. Id. at xi.
143. See id. at 3–5.
144. See id. at xxv.
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could still play an important role in setting the foundations for domestic
regulations regarding the GE mosquitoes.
B. Establishing a New Federal Regulatory Body:
Lessons From Mexico
Mexico also confronted a lack of preexisting structure for regulating
GE mosquitoes when it reviewed and approved a large outdoor field-cage
study with Oxitec’s OX3604C strain mosquitoes in a rural area near
Tapachula, Mexico.145  That strain is not the same as the OX513A that may
be released in Florida, and no mosquitoes were actually released into the
wild during the trial.146  Nonetheless, it is worthwhile to observe how the
regulatory system in Mexico treated this situation in order to see whether
any lessons can be learned and applied in the U.S. context.
The authors of the field study in Mexico stated that the keys to the
successful completion of the field experiment were engagement with the
community as well as Mexico’s “mature regulatory system for the use of
genetically modified organisms.”147  One analysis of the field study points to
three factors that were most important in allowing this contained field trial
in Mexico.148  The first factor was the existence of a federal-level regulatory
body CIBIOGEM (Comisio´n Intersecretarial de Bioseguridad de los Or-
ganismos Gene´ticamente Modificados).149  The second was the collabora-
tive efforts of world-class scientific institutions.150  The third was the
efficient decision-making processes of local communities.151
The second and third factors are also present in the U.S. regulatory
response.  The Mexican response differs from the U.S. based on their regu-
latory approach to the use of GE animals.  The U.S. government should not
have any trouble finding the world’s top experts in the field, and local orga-
nizations such as the Florida Keys Mosquito Control District facilitate dis-
cussions between Oxitec and the local residents.
The first factor is where Mexico differentiates itself in the efficient
regulation of GE animals.  CIBIOGEM is a federal-level commission that
comprises the heads of the Ministries of Health, Agriculture, Livestock,
Rural Development, Fisheries and Food (SAGARPA), Environment and
145. See Facchinelli et al., Field Cage Studies and Progressive Evaluation of Genetically-
Engineered Mosquitoes, 7 PLOS NEGLECTED TROPICAL DISEASES 1, 1–2 (2013).
146. Id. at 2.
147. Id.
148. See Ramsey et al., A Regulatory Structure for Working with Genetically Modified Mos-
quitoes: Lessons from Mexico, 8 PLOS NEGLECTED TROPICAL DISEASES 1, 8 (2014).
149. Id.
150. Id.
151. Id.
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Natural Resources (SEMARNAT), Finance and Public Credit, Economy
and Public Education, and the General Director of the National Council of
Science and Technology (CONACYT).152  CIBIOGEM legislation adopted
in 2008 to regulate “the activities of contained and confined use, experimen-
tal release, release in a pilot program, commercial release, trading, importa-
tion, and exportation of GMOs” implements the Law on Biosafety of
Genetically Modified Organisms.153
The Executive Office of the President in the United States also estab-
lished the Biotechnology Working Group under the Emerging Technologies
Interagency Policy Coordination Committee in 2015.154  This working
group includes representatives from the Executive Office of the President,
the EPA, FDA, and USDA.155  However, one key difference between this
working group and CIBIOGEM is that the purpose of the working group is
merely coordination between different government agencies while that of
CIBIOGEM includes the execution of legislation.156
Rather than leading the effort to legislate and implement new laws, the
Biotechnology Working Group in the U.S. merely asks the EPA, FDA, and
USDA to commission independent studies by external institutions such as
the National Academy of Sciences.157  A legislative effort designed to spe-
cifically address the issues relating to GE animals might be a better way of
dealing with new GE technologies rather than the method of trying to fit
the new technologies into an outdated regulatory scheme adopted by the
Coordinated Framework.
V. NEW REGULATORY SCHEMES SHOULD BE DEVISED SOON
As Oxitec’s Florida Keys Project is nearing its implementation, various
civil protests have arisen in response to anxiety among various interest
groups that Oxitec’s application will be approved.  An online petition op-
posing the application’s approval has been signed by more than 150,000 peo-
ple.158  A lawsuit has even been filed against the FDA for approving the
152. Francisco A. Laguna & Annapurna Nandyal, Genetically Modified Organisms in Mex-
ico, TRANSLEGAL (Aug. 20, 2013), https://translegalllc.wordpress.com/2013/08/20/genetically-
modified-organisms-in-mexico/comment-page-1.
153. Ramsey et al., supra note 148, at 4. R
154. Modernizing the Regulatory System for Biotechnology Products, supra note 96, at 3. R
155. Id.
156. See id. at 3–4; Ramsey et al., supra note 148, at 4. R
157. EXECUTIVE OFFICE OF THE PRESIDENT, NATIONAL STRATEGY FOR MODERNIZING THE REGULA-
TORY SYSTEM FOR BIOTECHNOLOGY PRODUCTS 14 (2016), https://www.epa.gov/sites/production/
files/2016-12/documents/biotech_national_strategy_final.pdf
158. GE Mosquito Petition, supra note 30. R
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project.159  While it remains to be seen whether such congregation of inter-
est groups could impose enough political pressure on the FDA, Oxitec has
made significant progress in preparing for the approval.160  Oxitec has al-
ready set up a lab in Marathon, Florida, for the purpose of importing mos-
quito eggs for injection of the self-limiting genes and the subsequent
rearing of adult mosquitoes for release.161
At the same time, new ambitious projects employing genetic engineer-
ing technologies are springing up to tackle similar problems in other regions
of the world, such as China.162  Also, the recent outbreak of the Zika virus
in a section of Miami Beach has raised significant alarm in the U.S.163
Human-driven science will consistently evolve to solve the world’s most
serious health problems.  New versions of Oxitec’s technology are being
researched by many labs around the world. For example, MIT has an-
nounced that its scientists are developing a technology called “gene drive” to
wipe out the population of mosquitoes that carry the Zika virus.164
In order to effectively facilitate such innovative technologies, Congress
should devise a new regulatory scheme that makes more intuitive sense
rather than merely relying on outdated statutory language.  The law is lag-
ging behind the science, and the regulatory shortcoming fails to foster the
public’s confidence in the legislative process.  Bridging the gap between sci-
ence and law is especially important as we enter into an increasingly techni-
cal time with emerging innovations such as autonomous vehicles,
sophisticated surveillance, and GM foods.  It is extremely important that
Congress take the responsibility for maintaining public faith in these com-
plex fields in order to maintain their status as the creators of our federal
law.
159. David Goodhue, Environmental Groups to Sue FDA Over Plan to Release Zika-Fighting
GMO Mosquitoes, GENETIC LITERACY PROJECT (Nov. 29, 2016), https://www.geneticlitera-
cyproject.org/2016/11/29/environmental-groups-sue-fda-plan-release-zika-fighting-gmo-mos
quitoes.
160. Alvarez, supra note 25. R
161. Id.
162. Cat DiStasio, World’s Largest ‘Mosquito Factory’ in China to Release 20 Million Bugs a
Week, INHABITAT (Mar. 30, 2016), http://inhabitat.com/worlds-largest-mosquito-factory-in-
china-to-release-20-million-bugs-a-week.
163. E.g., Tiffany Ap, Zika Virus: Miami Beach Transmission Zone Triples, CNN (Sept. 17,
2016 2:55 AM), http://www.cnn.com/2016/09/17/health/miami-beach-zika-zone-expanded/.
164. Antonio Regalado, We Have the Technology to Destroy All Zika Mosquitoes, MIT TECH-
NOLOGY REVIEW (Feb. 8, 2016), https://www.technologyreview.com/s/600689/we-have-the-
technology-to-destroy-all-zika-mosquitoes.
